Key Highlights
- Shares are up 4.85% pre-market to $0.84, building on a prior close of $0.80.
- The company launched generic ondansetron tablets in 4mg and 8mg strengths in the Canadian market, the generic equivalent of Zofran, used for nausea and vomiting from chemotherapy, radiation, and surgery.
- The global ondansetron market is projected to grow from $1.82 billion in 2025 to $2.98 billion by 2034, according to a third-party research estimate.
Sunshine Biopharma (NASDAQ:SBFM) shares are up 4.85% pre-market to $0.84, building on a prior close of $0.80, after the company launched generic ondansetron tablets in 4mg and 8mg strengths in the Canadian market. Ondansetron is the generic equivalent of Zofran, a prescription serotonin 5-HT3 receptor antagonist widely prescribed for nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery. By offering two strengths and film-coated tablets, the launch is intended to let healthcare providers better tailor treatment to individual patients.
The launch is supported by the established Canadian distribution network of the company's wholly owned subsidiary, Nora Pharma. The global ondansetron market was valued at $1.82 billion in 2025 and is projected to reach $2.98 billion by 2034, according to a third-party research estimate, growing at a compound annual rate of 5.6% as cancer diagnoses and surgical procedure volumes rise worldwide. The company's CEO said the launch represents a further step in scaling its generics Business and reflects its commitment to broadening access to needed pharmaceuticals.
A Portfolio Built for Scale
The company currently has 61 generic prescription drugs on the market in Canada, with approximately 11 additional drugs scheduled to launch in the remainder of 2026. That cadence of regular generic launches has become a core part of the company's growth strategy, leaning on Nora Pharma's existing distribution relationships rather than building new market access from scratch with each product.
Beyond the Generics Business
Alongside its generics portfolio, the company is also advancing a proprietary Drug Development program comprised of an mRNA-lipid nanoparticle candidate targeted for liver cancer and a small molecule protease inhibitor for treatment of coronavirus infections. These programs represent a longer-term, higher-risk complement to the steadier, revenue-generating generics business.
Why the Canadian Market Matters
The Canadian pharmaceutical market accounts for a meaningful share of global pharmaceutical spending and ranks among the largest markets worldwide, according to third-party industry data cited in the announcement, making it a natural focus for a generics company built around a Canadian distribution subsidiary.






Please wait processing your request...